Neuronetics reported a strong Q3 2025, with total revenue increasing 11% year-over-year, driven by robust performance in Greenbrook clinics and effective integration strategies.

• Total revenue reached $37.3 million, bolstered by a 25% increase in revenue at Greenbrook clinics.
• System sales for NeuroStar were solid, with 40 units shipped and consistent average selling prices exceeding targets.
• Treatment session utilization for NeuroStar grew by 11% compared to the prior year, indicating strong demand for its services.
• The underway integration of the Greenbrook business and expansion of the SPRAVATO rollout is poised to enhance operational efficiency and profitability.
• The company strategically optimized its RAM program, successfully scheduling over 350 physician meetings to drive referrals, resulting in over 2,200 patients referred in Q3.